Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank68
3Y CAGR-27.8%
5Y CAGR+19.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-27.8%/yr
vs -4.6%/yr prior
5Y CAGR
+19.4%/yr
Recent deceleration
Acceleration
-23.2pp
Decelerating
Percentile
P68
Within normal range
vs 5Y Ago
2.4x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 7.83% |
| Q3 2025 | 10.08% |
| Q2 2025 | -3.11% |
| Q1 2025 | 18.16% |
| Q4 2024 | -22.51% |
| Q3 2024 | -15.19% |
| Q2 2024 | -10.54% |
| Q1 2024 | 1.55% |
| Q4 2023 | 4.17% |
| Q3 2023 | 2.18% |
| Q2 2023 | 6.78% |
| Q1 2023 | -9.97% |
| Q4 2022 | 20.83% |
| Q3 2022 | -38.58% |
| Q2 2022 | 40.31% |
| Q1 2022 | -5.72% |
| Q4 2021 | 10.75% |
| Q3 2021 | -1.73% |
| Q2 2021 | 6.39% |
| Q1 2021 | 1.17% |
| Q4 2020 | 3.23% |
| Q3 2020 | 22.43% |
| Q2 2020 | -11.79% |
| Q1 2020 | 25.19% |
| Q4 2019 | -14.29% |
| Q3 2019 | 24.27% |
| Q2 2019 | -68.64% |
| Q1 2019 | 404.80% |
| Q4 2018 | -1.48% |
| Q3 2018 | 20.30% |
| Q2 2018 | 3.86% |
| Q1 2018 | 0.00% |